<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668382</url>
  </required_header>
  <id_info>
    <org_study_id>UM200702</org_study_id>
    <nct_id>NCT00668382</nct_id>
  </id_info>
  <brief_title>Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection</brief_title>
  <official_title>Phase I Study To Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Of Alpha-Gal Glycosphingolipids In Patients With Advanced Or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral
      injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced,
      refractory solid tumors who have failed standard therapies or are not eligible for standard
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intratumoral injection of alpha gal glycolipid in experimental knockout mouse model systems
      incorporates into tumor cell membranes and presents these xeno-transplantation epitopes to
      antigen presenting cells with that particular tumor's tumor associated antigens (TAA). Thus
      this maneuver converts any individual tumor into an in situ tumor vaccine without the need to
      isolate, purify or supply TAA exogenously. The effects in these model systems demonstrate
      both the upregulation of cytotoxic T cells which react against the particular tumor's TAA, as
      well as resolution of injected primary tumor and eradication and prevention of metastatic
      disease at distant sites. This current study was undertaken to investigate the safety and
      feasibility of such an approach in humans. The major toxicity concerns are acute allergic or
      complement activation reactions or development of autoimmunity. The primary treatment is a
      single intratumoral injection of alpha gal glycolipid. The study design is a standard dose
      escalation design and the primary endpoint is Dose limiting toxicity at one month after
      injection (grade 3 or 4. Subjects are followed until death utilizing standard clinical
      imaging and evaluation to judge overall tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Greater Than Grade 3 or 4 Toxicity</measure>
    <time_frame>1 month</time_frame>
    <description>Grade 3/4 Toxicity occurring in a participant within a month of intratumoral injection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Neoplasm Metastases</condition>
  <arm_group>
    <arm_group_label>Alpha-Gal Glycosphingolipid injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alpha-Gal Glycosphingolipid</intervention_name>
    <description>Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity</description>
    <arm_group_label>Alpha-Gal Glycosphingolipid injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with solid tumors who have failed standard therapies, or are not candidates
             for standard therapies.

          2. Patients must have at least one measurable lesion that is accessible and suitable for
             injection of the GSL alpha-GAL.

          3. Patients should not be undergoing any active treatment with chemotherapy,
             radiotherapy, or steroids (either because the patient or the treating physician have
             decided not to employ these therapies at this time, or because they had already been
             tried and failed). If they have been treated with these modalities, the treatments
             should have been completed at least two weeks prior to date of injection of GSL
             alpha-GAL.

          4. Patients should be judged by the investigator to be able to undergo safely the
             procedure needed to inject the tumor with GSL alpha-GAL.

          5. Age equal or over 18 years old.

          6. ECOG (Eastern Cooperative Oncology Group ) performance of less than 2. (International
             Normalized Ratio) INR less than 1.5 and a (Partial Thromboplastin Time) PTT no greater
             than normal limits within 1 week prior to intra-tumoral injection (For patients who
             requires invasive procedure for intra-tumoral injection).

          7. Laboratory Criteria (completed equal or less 2 weeks before enrollment) Hematologic:
             (White Blood Cell Count) WBC equal or above 3500/millimeter-cubed or (Absolute
             Neutrophil Count) ANC equal or above 1500/millimeter-cubed and platelet count equal or
             above 100,000/ millimeter-cubed.

             Hepatic: Total bilirubin equal or less 4.0 milligrams/deciliter. Renal: Creatinine
             equal or less 2.2 milligrams/deciliter.

          8. Patients must be negative for HIV (circulating antibody), Hepatitis B (circulating
             antigen), and Hepatitis C (circulating antibody).

          9. Patients should have an expected survival of more than 6 weeks and should not have
             other systemic anti-tumor treatments planned during this time frame.

        Exclusion Criteria:

          1. Patients who are pregnant (as determined by a positive serum HCG (Human Chorionic
             Gonadotropin) in patients of childbearing potential) or nursing.

          2. Patients under the age of 18.

          3. Patients with severe infections or septicemia.

          4. Patients with a history of autoimmune disease.

          5. Patients in, or about to be in, active treatment with chemotherapy or steroids.

          6. Patients who refuse HIV/hepatitis testing and patients who do not sign an approved
             consent form.

          7. Patient has received other investigational drugs within 14 days before enrollment or
             is expected to participate in an experimental drug study during this study treatment.

          8. Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giles Whalen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15;174(12):7516-23.</citation>
    <PMID>15944250</PMID>
  </results_reference>
  <results_reference>
    <citation>Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother. 2004 Oct;53(10):879-92. Epub 2004 Jul 28. Review.</citation>
    <PMID>15338206</PMID>
  </results_reference>
  <results_reference>
    <citation>DiGiacomo A, North RJ. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J Exp Med. 1986 Oct 1;164(4):1179-92. Erratum in: J Exp Med 1986 Dec 1;164(6):2131.</citation>
    <PMID>2944983</PMID>
  </results_reference>
  <results_reference>
    <citation>Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999 Nov 15;163(10):5211-8.</citation>
    <PMID>10553041</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <results_first_submitted>October 25, 2012</results_first_submitted>
  <results_first_submitted_qc>October 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2012</results_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Giles Whalen</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancerous solid tumors</keyword>
  <keyword>Alpha-Gal Glycosphingolipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from medical and surgical oncology clinics with currently untreatable tumors from march 2007 through June 2011</recruitment_details>
      <pre_assignment_details>No assignment to separate arms, Patients had to be off any active treatment for their advanced tumors for at least 2 weeks before entry onto study and a month after. Two subjects withdrew after screening and consent because of stroke (1) and insurance refusal(1). Two patients dropped out in the first month due to treatment needs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alpha-Gal Glycosphingolipid Injection</title>
          <description>Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">beginning of trial</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alpha-Gal Glycosphingolipid Injection</title>
          <description>Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Greater Than Grade 3 or 4 Toxicity</title>
        <description>Grade 3/4 Toxicity occurring in a participant within a month of intratumoral injection</description>
        <time_frame>1 month</time_frame>
        <population>Dose escalating Phase 1 scheme: three participants for each dose cohort. The second patient in the last (10 mg) dose cohort developed and adverse event (infection at injection site) and so three more participants were entered and analyzed at that dose</population>
        <group_list>
          <group group_id="O1">
            <title>Intratumoral Injection</title>
            <description>Single Intratumoral injection of Alpha Gal Glycosphingolipid. Three dose cohorts (0.1mg, 1mg, 10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Greater Than Grade 3 or 4 Toxicity</title>
          <description>Grade 3/4 Toxicity occurring in a participant within a month of intratumoral injection</description>
          <population>Dose escalating Phase 1 scheme: three participants for each dose cohort. The second patient in the last (10 mg) dose cohort developed and adverse event (infection at injection site) and so three more participants were entered and analyzed at that dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over one month</time_frame>
      <desc>patients followed for as long as they lived per clinical care protocols</desc>
      <group_list>
        <group group_id="E1">
          <title>Intratumoral Injection</title>
          <description>Single Intratumoral injection of Alpha Gal Glycosphingolipid. Three dose cohorts (0.1mg, 1mg, 10mg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>surgical site infection</sub_title>
                <description>Patient developed an abscess (UGI flora) at an injection site in the pancreatic body one week after injection via an EUS guided approach. This required hospitalization, IV antibiotics and drains placed by interventional radiology. Subject recovered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No allergic/immune toxicity. The single toxicity/AE was bacterial infection with UGI flora at injection site following EUS (endoscopic ultra-sound) guided injection of pancreatic cancer. Added injections covered with antibiotic prophylaxis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sheila Noone</name_or_title>
      <organization>UMass Medical Scool</organization>
      <phone>508 856 5015</phone>
      <email>Sheil.Noone@umasmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

